Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting.
|
Free SPRO Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.33 out of 4) 46th percentile
(ranked lower than approx. 54% of all stocks covered)
Analysts' Target Price: SPRO Stock Forecast Based on Zacks ABR data; powered by Xignite |